Transcending the Challenge of Evolving Resistance Mechanisms in Through β-lactam-enhancer-mechanism-based Cefepime/zidebactam
Overview
Authors
Affiliations
Compared to other genera of Gram-negative pathogens, is adept in acquiring complex non-enzymatic and enzymatic resistance mechanisms thus remaining a challenge to even novel antibiotics including recently developed β-lactam and β-lactamase inhibitor combinations. This study shows that the novel β-lactam enhancer approach enables cefepime/zidebactam to overcome both non-enzymatic and enzymatic resistance mechanisms associated with a challenging panel of . This study highlights that the β-lactam enhancer mechanism is a promising alternative to the conventional β-lactam/β-lactamase inhibitor approach in combating ever-evolving MDR .
Outeda-Garcia M, Arca-Suarez J, Lence E, Rodriguez-Coello A, Maceiras R, Blanco-Martin T Antimicrob Agents Chemother. 2025; 69(2):e0161424.
PMID: 39791889 PMC: 11823609. DOI: 10.1128/aac.01614-24.
Bakthavatchalam Y, Behera B, Shah A, Mathur P, Ray R, Fomda B Microbiol Spectr. 2024; 13(1):e0049724.
PMID: 39560385 PMC: 11705784. DOI: 10.1128/spectrum.00497-24.
Cefepime-Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Zhanel G, Mansour C, Mikolayanko S, Lawrence C, Zelenitsky S, Ramirez D Drugs. 2024; 84(10):1219-1250.
PMID: 39214942 DOI: 10.1007/s40265-024-02082-9.
Soman R, Sirsat R, Sunavala A, Punatar N, Mehta J, Rodrigues C Eur J Clin Microbiol Infect Dis. 2024; .
PMID: 38416290 DOI: 10.1007/s10096-024-04791-1.